By Stephen Nakrosis 
 

NeuroMetrix, Inc. (NURO) on Tuesday said the company and GlaxoSmithKline PLC (GSK) agreed to co-fund future development of Quell technology beginning in 2019, "subject to agreement on an annual program of product initiatives."

NeuroMetrix said the 2019 development program will commence in January.

The two companies also modified terms of their collaboration which will see the up to $13.8 million remaining to be paid by GlaxoSmithKline upon the achievement of certain milestones reallocated. NeuroMetrix said it received a $2 million milestone payment from GlaxoSmithKline in connection with such modifications.

In January, the two companies announced a collaboration which saw GSK acquire exclusive ownership of Quell technology for markets outside the U.S., while NeuroMetrix retained exclusive ownership in the U.S. market. Quell is a wearable device designed to ease chronic pain.

Trading in NeuroMetrix shares had been briefly halted Tuesday afternoon prior to the announcement. At 1:42 p.m. EST, shares were trading up 15.87% at 98 cents per share.

American depository receipts of GlaxoSmithKline were trading down 0.78% at $37.38.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 11, 2018 14:03 ET (19:03 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.